Altimmune (ALT) Intangibles (2015 - 2023)
Altimmune (ALT) posted quarterly Intangibles of $12.4 million for Q3 2023, little changed year-over-year from $12.4 million in Q3 2022, and little changed quarter-over-quarter from $12.4 million in Q2 2023.
Altimmune (ALT) Intangibles (2015 - 2023) Analysis & Trends
Altimmune (ALT) has reported Intangibles for 9 consecutive years, with $12.4 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Intangibles changed 0.0% year-over-year to $12.4 million; the TTM figure through Sep 2023 stood at $12.4 million (changed 0.0% YoY), while the FY2022 annual figure was $12.4 million, down 9.9% from the prior year.
- Intangibles was little changed at $12.4 million in Q3 2023 per ALT's latest filing, from $12.4 million in the prior quarter.
- Across five years, Intangibles topped out at $14.5 million in Q4 2019 and bottomed at $12.4 million in Q1 2022.
- Historically, Intangibles has averaged $13.0 million across 5 years, with a median of $12.8 million in 2020.
- Annual changes were most pronounced in 2019 — Intangibles plunged 67.22% — and 2021, when it rose 7.48%.
- Altimmune's Intangibles stood at $14.5 million in 2019, then fell by 11.26% to $12.8 million in 2020, then increased by 7.48% to $13.8 million in 2021, then decreased by 9.9% to $12.4 million in 2022, then changed by 0.0% to $12.4 million in 2023.
- Business Quant data shows ALT's Intangibles at $12.4 million in Q3 2023, $12.4 million in Q2 2023, and $12.4 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 12.42 Mn |
| Jun 30, 2023 | 12.42 Mn |
| Mar 31, 2023 | 12.42 Mn |
| Dec 31, 2022 | 12.42 Mn |
| Sep 30, 2022 | 12.42 Mn |
| Jun 30, 2022 | 12.42 Mn |
| Mar 31, 2022 | 12.42 Mn |
| Dec 31, 2021 | 13.78 Mn |
| Sep 30, 2021 | 12.99 Mn |
| Jun 30, 2021 | 12.96 Mn |
| Mar 31, 2021 | 13.65 Mn |
| Dec 31, 2020 | 12.82 Mn |
| Sep 30, 2020 | 13.55 Mn |
| Jun 30, 2020 | 12.79 Mn |
| Mar 31, 2020 | 12.74 Mn |
| Dec 31, 2019 | 14.45 Mn |
| Sep 30, 2019 | 12.74 Mn |
| Jun 30, 2019 | 13.76 Mn |
| Mar 31, 2019 | 13.76 Mn |
| Dec 31, 2018 | 13.85 Mn |